Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib vs High-Dose Imatinib in CP-CML
NCT00362466Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2007
- Primary completion
- Jun 2008
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dasatinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Complete Cytogenetic Response Rate at 6 months. Started Apr 2007; status: terminated.
02
Drugs
dasatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00362466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362466.